Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRMNASDAQ:PHARNASDAQ:SDGRNASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$39.10+0.9%$45.23$23.14▼$54.23$1.92B1523,007 shs429,075 shsPHARPharming Group$8.02-1.7%$8.52$6.65▼$11.07$545.61M-0.086,361 shs2,415 shsSDGRSchrödinger$25.75+2.1%$22.01$16.60▼$28.47$1.88B1.77824,246 shs1.14 million shsVCELVericel$41.23+1.0%$47.42$37.76▼$63.00$2.07B1.61391,554 shs343,268 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals+0.90%-0.05%-11.76%-16.72%+63.94%PHARPharming Group-0.87%+0.88%-8.86%-19.88%-21.14%SDGRSchrödinger+2.14%+33.98%+12.45%+35.53%+2.84%VCELVericel+1.00%-1.60%-10.95%-30.20%-10.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMIRMMirum Pharmaceuticals3.9581 of 5 stars3.50.00.04.23.43.30.6PHARPharming Group2.7239 of 5 stars3.55.00.00.02.90.00.6SDGRSchrödinger2.5335 of 5 stars3.51.00.00.03.72.50.6VCELVericel2.6293 of 5 stars3.51.00.00.03.20.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 3.09Buy$58.2048.85% UpsidePHARPharming Group 3.00Buy$30.00274.06% UpsideSDGRSchrödinger 3.00Buy$33.0028.16% UpsideVCELVericel 3.00Buy$60.8647.60% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, VCEL, MIRM, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.004/11/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $51.003/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/14/2025PHARPharming GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $39.003/14/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/3/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$67.00 ➝ $61.002/28/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.002/28/2025VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.002/27/2025MIRMMirum PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$50.00 ➝ $55.002/27/2025SDGRSchrödingerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.002/3/2025VCELVericelCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$64.00 ➝ $67.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$336.89M5.69N/AN/A$5.33 per share7.34PHARPharming Group$297.20M1.84$0.09 per share91.82$3.26 per share2.46SDGRSchrödinger$207.54M9.06$0.69 per share37.42$7.60 per share3.39VCELVericel$237.22M8.71$0.01 per share3,081.95$4.73 per share8.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$163.41M-$1.85N/AN/AN/A-31.69%-41.22%-14.81%5/6/2025 (Estimated)PHARPharming Group-$10.55M-$0.17N/A267.33N/A-6.09%-7.65%-3.82%5/6/2025 (Estimated)SDGRSchrödinger$40.72M-$2.57N/AN/AN/A-91.84%-35.77%-24.51%4/29/2025 (Estimated)VCELVericel-$3.18M$0.18687.2893.70N/A1.56%1.48%0.96%5/6/2025 (Estimated)Latest PHAR, VCEL, MIRM, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35N/AN/AN/AN/AN/A5/14/2025Q1 2025VCELVericel-$0.09N/AN/AN/A$53.86 millionN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81N/AN/AN/A$54.60 millionN/A3/13/2025Q4 2024PHARPharming Group$0.07$0.05-$0.02$0.05$76.67 million$92.70 million2/26/2025Q4 2024MIRMMirum Pharmaceuticals-$0.27-$0.49-$0.22-$0.49$96.64 million$99.41 million2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.333.343.15PHARPharming Group0.413.532.76SDGRSchrödingerN/A4.114.11VCELVericelN/A4.614.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/APHARPharming Group0.03%SDGRSchrödinger79.05%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals22.87%PHARPharming Group2.07%SDGRSchrödinger8.60%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14049.01 million37.03 millionOptionablePHARPharming Group28068.03 million66.62 millionNot OptionableSDGRSchrödinger79073.04 million66.59 millionOptionableVCELVericel30050.14 million46.79 millionOptionablePHAR, VCEL, MIRM, and SDGR HeadlinesRecent News About These CompaniesXTX Topco Ltd Makes New $1.14 Million Investment in Vericel Co. (NASDAQ:VCEL)April 18 at 5:09 AM | marketbeat.comBessemer Group Inc. Increases Stake in Vericel Co. (NASDAQ:VCEL)April 18 at 4:12 AM | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Bought by Townsquare Capital LLCApril 17 at 5:08 AM | marketbeat.comCerity Partners LLC Reduces Holdings in Vericel Co. (NASDAQ:VCEL)April 16 at 3:55 AM | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Sold by Fmr LLCApril 16 at 3:55 AM | marketbeat.comVericel price target lowered to $60 from $63 at BTIGApril 15 at 8:07 PM | markets.businessinsider.comInvesco Ltd. Has $122.90 Million Stake in Vericel Co. (NASDAQ:VCEL)April 15 at 4:58 AM | marketbeat.comGeode Capital Management LLC Purchases 12,062 Shares of Vericel Co. (NASDAQ:VCEL)April 15 at 4:20 AM | marketbeat.comVericel Co. (NASDAQ:VCEL) Stock Position Lifted by LPL Financial LLCApril 14, 2025 | marketbeat.comTruist Financial Lowers Vericel (NASDAQ:VCEL) Price Target to $51.00April 13, 2025 | marketbeat.comNeuberger Berman Group LLC Buys 55,555 Shares of Vericel Co. (NASDAQ:VCEL)April 13, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Price Target Lowered to $51.00 at Truist FinancialApril 13, 2025 | americanbankingnews.comInsider Selling: Vericel Co. (NASDAQ:VCEL) CEO Sells 24,850 Shares of StockApril 12, 2025 | insidertrades.comVericel price target lowered to $51 from $61 at TruistApril 11, 2025 | markets.businessinsider.comVericel (NASDAQ:VCEL) Sets New 52-Week Low - Should You Sell?April 9, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Purchased by Federated Hermes Inc.April 9, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Bought by JPMorgan Chase & Co.April 9, 2025 | marketbeat.com88,944 Shares in Vericel Co. (NASDAQ:VCEL) Acquired by Trexquant Investment LPApril 7, 2025 | marketbeat.comWellington Management Group LLP Acquires 701,064 Shares of Vericel Co. (NASDAQ:VCEL)April 7, 2025 | marketbeat.comKLP Kapitalforvaltning AS Makes New Investment in Vericel Co. (NASDAQ:VCEL)April 5, 2025 | marketbeat.comVericel is Now Oversold (VCEL)April 3, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?4 Healthcare Stocks With Massive Gains—and More to ComeBy Sarah Horvath | March 29, 2025View 4 Healthcare Stocks With Massive Gains—and More to ComeWhich Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?Pharma Frenzy: Volatility Ignites Biotech SectorBy Jeffrey Neal Johnson | March 25, 2025View Pharma Frenzy: Volatility Ignites Biotech Sector3 Biopharmaceutical Stocks Bucking the Sell-OffBy Nathan Reiff | April 10, 2025View 3 Biopharmaceutical Stocks Bucking the Sell-OffPHAR, VCEL, MIRM, and SDGR Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$39.10 +0.35 (+0.90%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$39.12 +0.02 (+0.04%) As of 04/17/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Pharming Group NASDAQ:PHAR$8.02 -0.14 (-1.72%) Closing price 04/17/2025 03:09 PM EasternExtended Trading$8.39 +0.37 (+4.61%) As of 04/17/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Schrödinger NASDAQ:SDGR$25.75 +0.54 (+2.14%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$25.60 -0.15 (-0.56%) As of 04/17/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Vericel NASDAQ:VCEL$41.23 +0.41 (+1.00%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$41.20 -0.02 (-0.06%) As of 04/17/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
